主要文件

查看所有文档

B1115000

苯扎贝特

Name: 苯扎贝特
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

2- [4- [2-（4-氯苯甲酰胺基）苄]苯氧基] -2-甲基丙酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₂₀ClNO₄

化学文摘社编号:

41859-67-0

分子量:

361.82

NACRES:

NA.24

PubChem Substance ID:

329773164

UNSPSC Code:

41116107

MDL number:

MFCD00078970

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

bezafibrate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O

InChI

1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)

InChI key

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465), PPARD(5467), PPARG(5468)

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bezafibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。

过氧化物酶体增殖物激活受体（PPAR）是类固醇核受体超家族成员之一。苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under 苯扎贝特

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

R Manfredi et al.

The Journal of infection, 42(3), 181-188 (2001-09-08)

To assess the correlation between antiretroviral treatment and dyslipidaemia in HIV-infected patients, and the role of bezafibrate as a lipid-lowering agent. We retrospectively compared serum lipid levels of five groups of 40 patients, each of them treated with either saquinavir

Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

U de Faire et al.

European heart journal, 17 Suppl F, 37-42 (1996-12-01)

Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol.

Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.

C G Ericsson

European heart journal, 19 Suppl H, H37-H41 (1998-08-26)

Bezafibrate is a latest generation fibrate derivative that substantially reduces total plasma cholesterol and triglyceride concentrations and increases high density lipoprotein (HDL) cholesterol. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a double-blind, placebo-controlled trial over 5 years to assess

查看所有相关文献

全球贸易项目编号

货号	GTIN
B1115000	04061833791363